RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA
Clinical trials for RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with relapsed leukemia: imetelstat combo trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) in children and young adults up to age 18 whose leukemia (AML, MDS, or JMML) has returned or not responded to treatment. The main goal is to find the safest…
Matched conditions: RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
Engineered immune cells take on childhood leukemia in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called FOLR1 CAR T cells for children up to age 6 whose acute myeloid leukemia (AML) has returned or not responded to standard therapy. The treatment involves taking the child's own immune cells, modifying them in a lab to recognize an…
Matched conditions: RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…
Matched conditions: RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:03 UTC